[Effectiveness of sodium cromoglycate in the reduction of bronchodilator doses in asthmatic patients].
Thirty asthmatic patients, ages ranging from 6 to 72 years, who were submitted to a 14 weeks clinical evaluation, were studied measuring the severity of dysnea, coughing, expectoration and wheezing. Sodium chromoglycate (SCG) was administered in aerosol starting the second week of the study and the doses of bronchial dilators was reduced starting the fourth week, with a 25% decrease in the total established initial dosage, every two weeks. In this study, SCG showed to be useful in decreasing symptoms caused by bronchial hyperreactivity and the use of bronchial dilators in 70% of asthmatics who react with the presence of just one risk factor (cold, the most frequent).
Bolaños Ancona
J C
JC
Servicio de alergia e inmunología, Centro Médico 20 de Noviembre, ISSSTE, México, D.F.
Espinosa Morales
S M
SM
Miranda Feria
A J
AJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D004205:Cromolyn Sodium / Q000494:pharmacology / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D001993:Bronchodilator Agents; D004205:Cromolyn Sodium
Efectividad del cromoglicato de sodio en la reducción de las dosis de broncodilatadores en pacientes asmáticos.